Nature Reviews Rheumatology - Table of Contents alert Volume 12 Issue 8

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
August 2016 Volume 12 Number 8
Impact Factor 10.531 *	In this issue Research Highlights News and Views Reviews Also this month  Featured article: Treatment of primary Sjögren syndrome Alain Saraux, Jacques-Olivier Pers & Valérie Devauchelle-Pensec
Subscribe   Facebook   RSS   Recommend to library   Twitter
RESEARCH HIGHLIGHTS Top Vasculitis syndromes: Updated recommendations for ANCA-associated vasculitis — working together Published online: 14 July 2016 p435 | doi:10.1038/nrrheum.2016.122 PDF Paediatric rheumatology: Novel Treg cell subset discovered in JIA Published online: 07 July 2016 p436 | doi:10.1038/nrrheum.2016.115 PDF Lupus nephritis: NRF2, a novel target in steroid-refractory LN? Published online: 07 July 2016 p436 | doi:10.1038/nrrheum.2016.116 PDF Autoimmunity: DNASE1L3 prevents anti-DNA responses Published online: 14 July 2016 p437 | doi:10.1038/nrrheum.2016.111 PDF Rheumatoid arthritis: Adalimumab drives Treg cell expansion via membrane TNF Published online: 23 June 2016 p438 | doi:10.1038/nrrheum.2016.109 PDF Connective tissue diseases: OX40L inhibition blocks tissue fibrosis Published online: 30 June 2016 p438 | doi:10.1038/nrrheum.2016.110 PDF IN BRIEF Rheumatoid arthritis: U-Act-Early finds tocilizumab favours RA remission | Stem cells: Stem cell therapy seems safe in refractory RA | Therapy: Patients with TRAPS respond to canakinumab | Vasculitis syndromes: 16S RNA sequencing sheds light on Behçet disease PDF
NEWS AND VIEWS		Top
Autoimmunity: Interferon α or β: which is the culprit in autoimmune disease? Mary K. Crow Published online: 14 July 2016 p439 | doi:10.1038/nrrheum.2016.117 Type I interferons contribute to the pathogenesis of several autoimmune diseases, with each interferon being preferentially produced in different settings by different cells. Could knowing which one is predominant in a given disease — or patient — lead to better therapies? Full Text | PDF
Spondyloarthropathies: CVD prevention and statin therapy in ankylosing spondylitis Anne Grete Semb & Silvia Rollefstad Published online: 30 June 2016 p441 | doi:10.1038/nrrheum.2016.103 Statin treatment is a cornerstone in the prevention of cardiovascular disease, but questions remain regarding its effects in patients with ankylosing spondylitis. Is there enough evidence supporting the use of statins in these patients? Full Text | PDF
Autoimmunity: Do IgM antibodies protect against atherosclerosis in SLE? Maureen McMahon & Brian Skaggs Published online: 30 June 2016 p442 | doi:10.1038/nrrheum.2016.108 Autoantibodies against end products of lipid peroxidation have unexpected effects on atherosclerosis in systemic lupus erythematosus (SLE). The discovery of their effects could lead to new theories about the role of the adaptive immune system in SLE. Full Text | PDF
Rheumatoid arthritis: Glucocorticoid therapy and body composition Frank Buttgereit & Gerd R. Burmester Published online: 07 July 2016 p444 | doi:10.1038/nrrheum.2016.114 Glucocorticoids are cost-effective drugs that exert strong anti-inflammatory and immunosuppressive effects. However, there is increasing awareness of their potential adverse effects. Although Cushingoid appearance and weight gain have been known for decades, modern measurements of body composition now enable detailed insights into glucocorticoid-induced changes in fat mass and redistribution. Full Text | PDF
REVIEWS		Top
The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions Shahla Abdollahi-Roodsaz, Steven B. Abramson & Jose U. Scher Published online: 03 June 2016 p446 | doi:10.1038/nrrheum.2016.68 This Review provides an overview of new discoveries that are changing our understanding of the complex role of the human gut microbiota and its metabolites in health and disease, including their effects on rheumatic diseases. Factors that modulate the microbiota, such as diet and probiotics, and advances in pharmacomicrobiomics are also discussed. Abstract | Full Text | PDF
Treatment of primary Sjögren syndrome Alain Saraux, Jacques-Olivier Pers & Valérie Devauchelle-Pensec Published online: 14 July 2016 p456 | doi:10.1038/nrrheum.2016.100 This Review discusses the current treatment of the manifestations of primary Sjogren syndrome and summarizes ongoing clinical trials. The authors examine the status of biologic therapies, the challenges relating to clinical trial design and potential targets for the future therapies. Abstract | Full Text | PDF | Supplementary information
Macrophage heterogeneity in the context of rheumatoid arthritis Irina A. Udalova, Alberto Mantovani & Marc Feldmann Published online: 07 July 2016 p472 | doi:10.1038/nrrheum.2016.91 Macrophages, which have roles in the pathogenesis and resolution of rheumatoid arthritis, consist of a heterogeneous population of cells with different origins and functions. This Review describes these properties, and considers the potential for therapeutic targeting of specific macrophage subtypes. Abstract | Full Text | PDF
Insight into rheumatological cause and effect through the use of Mendelian randomization Philip C. Robinson, Hyon K. Choi, Ron Do & Tony R. Merriman Published online: 14 July 2016 p486 | doi:10.1038/nrrheum.2016.102 Mendelian randomization analysis makes use of random inheritance of genetic variants to limit confounding in tests for causal relationships between risk factors and disease outcomes. This Review considers the current and future applications, as well as the limitations, of Mendelian randomization in rheumatology. Abstract | Full Text | PDF | Supplementary information
Corrigendum: The genetics of bone mass and susceptibility to bone diseases David Karasik, Fernando Rivadeneira & Mark L. Johnson Published online: 22 July 2016 p496 | doi:10.1038/nrrheum.2016.118 Full Text | PDF
Erratum: Deregulation and therapeutic potential of microRNAs in arthritic diseases Rita Vicente, Danièle Noël, Yves-Marie Pers, Florence Apparailly & Christian Jorgensen Published online: 14 July 2016 p496 | doi:10.1038/nrrheum.2016.119 Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2015. Nature Reviews Rheumatology was previously published as Nature Clinical Practice Rheumatology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.